Aqueous Humor Proteomic Alterations Associated with Visual Field Index Parameters in Glaucoma Patients: A Pilot Study

被引：12
作者：
Kodeboyina, Sai Karthik [1 ]
Lee, Tae Jin [1 ]
Bollinger, Kathryn [2 ]
Ulrich, Lane [2 ]
Bogorad, David [2 ]
Estes, Amy [2 ]
Zhi, Wenbo [1 ]
Sharma, Shruti [1 ,2 ]
Sharma, Ashok [1 ,3 ]
机构：
[1] Augusta Univ, Med Coll Georgia, Ctr Biotechnol & Genom Med, Augusta, GA 30912 USA
[2] Augusta Univ, Dept Ophthalmol, Med Coll Georgia, Augusta, GA 30912 USA
[3] Augusta Univ, Dept Populat Hlth Sci, Med Coll Georgia, Augusta, GA 30912 USA
来源：
JOURNAL OF CLINICAL MEDICINE | 2021年 / 10卷 / 06期
关键词：
aqueous humor; glaucoma; mass spectrometry; proteomics; visual field; TRABECULAR MESHWORK; MUTATIONS; PATHWAYS; CDHR1;
D O I：
10.3390/jcm10061180
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Purpose: The purpose of this study was to discover the aqueous humor proteomic changes associated with visual field indices in glaucoma patients. Methods: Aqueous humor samples were analyzed using Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS). The visual fields were analyzed with the Humphrey Visual Field analyzer. Statistical analyses were performed to discover the relationship between the aqueous humor proteins and visual field parameters including Pattern Standard Deviation (PSD), Visual Field Index (VFI), Mean Deviation (MD) and Glaucoma Hemifield Test (GHT). Results: In total, 222 proteins were identified in 49 aqueous humor samples. A total of 11, 9, 7, and 6 proteins were significantly correlated with PSD, VFI, MD, and GHT respectively. These proteins include apolipoprotein D, members of complement pathway (C1S, C4A, C4B, C8B, and CD14), and immunoglobulin family (IKHV3-9, IGKV2-28). Conclusion: Several proteins involved in immune responses (immunoglobulins and complement factors) and neurodegeneration (apolipoprotein D) were identified to be associated with abnormal visual field parameters. These findings provide targets for future studies investigating precise molecular mechanisms and new therapies for glaucomatous optic neuropathy.
引用
收藏
页码：1 / 10
页数：10
相关论文
共 46 条
[41]   Visual field loss in patients with normal-tension glaucoma under topical nipradilol or timolol: Subgroup and subfield analyses of the nipradilol-timolol study [J].
Araie, Makoto ;
Shirato, Shiroaki ;
Yamazaki, Yoshio ;
Kitazawa, Yoshiaki ;
Ohashi, Yasuo .
JAPANESE JOURNAL OF OPHTHALMOLOGY, 2010, 54 (04) :278-285
[42]   Visual field loss in patients with normal-tension glaucoma under topical nipradilol or timolol: Subgroup and subfield analyses of the nipradilol-timolol study [J].
Makoto Araie ;
Shiroaki Shirato ;
Yoshio Yamazaki ;
Yoshiaki Kitazawa ;
Yasuo Ohashi .
Japanese Journal of Ophthalmology, 2010, 54 :278-285
[43]   Lack of Association of rs1192415 in TGFBR3-CDC7 With Visual Field Progression: A Cohort Study in Chinese Open Angle Glaucoma Patients [J].
Chen, Yuhong ;
Qiu, Chen ;
Qian, Shaohong ;
Chen, Junyi ;
Chen, Xueli ;
Wang, Li ;
Sun, Xinghuai .
FRONTIERS IN GENETICS, 2018, 9
[44]   Association between Serum Potassium with Risk of Onset and Visual Field Progression in Patients with Primary Angle Close Glaucoma: A Cross-Sectional and Prospective Cohort Study [J].
Qiu, Yichao ;
Wei, Jiaojiao ;
Yu, Jian ;
Li, Yingzhu ;
Shao, Mingxi ;
Ren, Jun ;
Cao, Wenjun ;
Li, Shengjie ;
Sun, Xinghuai .
OXIDATIVE MEDICINE AND CELLULAR LONGEVITY, 2022, 2022
[45]   Predictive Value of Dynamic Corneal Response Parameters Evaluated with Scheimpflug High-Speed Video (Corvis ST) on the Visual Field Progression in Prostaglandin Treated Ocular Hypertension and Open-Angle Glaucoma Patients [J].
Marta I. Martinez-Sánchez ;
Gema Bolívar ;
Anna Dastiridou ;
Purificación Escámez ;
Miguel A. Teus .
Ophthalmology and Therapy, 2023, 12 :3177-3186
[46]   Predictive Value of Dynamic Corneal Response Parameters Evaluated with Scheimpflug High-Speed Video (Corvis ST) on the Visual Field Progression in Prostaglandin Treated Ocular Hypertension and Open-Angle Glaucoma Patients [J].
Martinez-Sanchez, Marta I. ;
Bolivar, Gema ;
Dastiridou, Anna .
OPHTHALMOLOGY AND THERAPY, 2023, 12 (06) :3177-3186
12345